These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 15767241)

  • 21. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients.
    Catapano AL; Davidson MH; Ballantyne CM; Brady WE; Gazzara RA; Tomassini JE; Tershakovec AM
    Curr Med Res Opin; 2006 Oct; 22(10):2041-53. PubMed ID: 17022864
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of rosuvastatin compared with other statins from a managed care perspective.
    Benner JS; Smith TW; Klingman D; Tierce JC; Mullins CD; Pethick N; O'Donnell JC
    Value Health; 2005; 8(6):618-28. PubMed ID: 16283862
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II.
    Ballantyne CM; Bertolami M; Hernandez Garcia HR; Nul D; Stein EA; Theroux P; Weiss R; Cain VA; Raichlen JS
    Am Heart J; 2006 May; 151(5):975.e1-9. PubMed ID: 16644314
    [TBL] [Abstract][Full Text] [Related]  

  • 24. LDL-C reductions and goal attainment among naive statin users in the Netherlands: real life results.
    Heintjes EM; Hirsch MW; van der Linden MW; O'Donnell JC; Stalenhoef AF; Herings RM
    Curr Med Res Opin; 2008 Aug; 24(8):2241-50. PubMed ID: 18578957
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of low-density lipoprotein cholesterol reduction after switching patients on other statins to rosuvastatin or simvastatin in a real-world clinical practice setting.
    Fox KM; Gandhi SK; Ohsfeldt RL; Davidson MH
    Am J Manag Care; 2007 Dec; 13 Suppl 10():S270-5. PubMed ID: 18095777
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of rosuvastatin versus atorvastatin in Hispanic-Americans with hypercholesterolemia (from the STARSHIP trial).
    Lloret R; Ycas J; Stein M; Haffner S;
    Am J Cardiol; 2006 Sep; 98(6):768-73. PubMed ID: 16950182
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of rosuvastatin versus ezetimibe/simvastatin in managing dyslipidemic patients in Mexico.
    Briseño GG; Mino-León D
    Curr Med Res Opin; 2010 May; 26(5):1075-81. PubMed ID: 20225991
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
    Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study).
    Ballantyne CM; Weiss R; Moccetti T; Vogt A; Eber B; Sosef F; Duffield E;
    Am J Cardiol; 2007 Mar; 99(5):673-80. PubMed ID: 17317370
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and cost of HMG-CoA reductase inhibitors in the treatment of patients with primary hyperlipidemia.
    Perreault S; Levinton C; Le Lorier J
    Can J Clin Pharmacol; 2000; 7(3):144-54. PubMed ID: 11044760
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome.
    Deedwania PC; Hunninghake DB; Bays HE; Jones PH; Cain VA; Blasetto JW;
    Am J Cardiol; 2005 Feb; 95(3):360-6. PubMed ID: 15670545
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of rosuvastatin every other day compared with once daily in patients with hypercholesterolemia.
    Wongwiwatthananukit S; Sansanayudh N; Dhummauppakorn R; Kitiyadisai C
    Ann Pharmacother; 2006 Nov; 40(11):1917-23. PubMed ID: 17003082
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expanding options with a wider range of rosuvastatin doses.
    Olsson AG
    Clin Ther; 2006 Nov; 28(11):1747-63. PubMed ID: 17212997
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Achieving lipid goals in real life: the Dutch DISCOVERY study.
    Bots AF; Kastelein JJ;
    Int J Clin Pract; 2005 Dec; 59(12):1387-94. PubMed ID: 16351669
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Achieving 2003 European lipid goals with rosuvastatin and comparator statins in 6743 patients in real-life clinical practice: DISCOVERY meta-analysis.
    Middleton A; Binbrek AS; Fonseca FA; Wilpshaar W; Watkins C; Strandberg TE
    Curr Med Res Opin; 2006 Jun; 22(6):1181-91. PubMed ID: 16846551
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical and economic outcomes in patients switched to simvastatin in a community-based family medicine practice.
    Willey VJ; Reinhold JA; Willey KH; Kelly BL; Cziraky MJ
    Int J Clin Pract; 2010 Aug; 64(9):1235-8. PubMed ID: 20653799
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of switching statins on lipid and apolipoprotein ratios in the MERCURY I study.
    Cheung RC; Morrell JM; Kallend D; Watkins C; Schuster H
    Int J Cardiol; 2005 Apr; 100(2):309-16. PubMed ID: 15823640
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of direct-to-consumer advertising of hydroxymethylglutaryl coenzyme a reductase inhibitors on attainment of LDL-C goals.
    Bradford WD; Kleit AN; Nietert PJ; Ornstein S
    Clin Ther; 2006 Dec; 28(12):2105-18; discussion 2104. PubMed ID: 17296467
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia.
    Davidson MH
    Expert Opin Investig Drugs; 2002 Mar; 11(3):125-41. PubMed ID: 12769127
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S; Ridker PM
    Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.